From: xxxxxx.xxxxxxx@xx.xxxxxx.xx <xxxxxx.xxxxxxx@xx.xxxxxx.xx>
Sent: Wednesday, September 9, 2020 9:11 AM
To:
Cc:
@gesundheitsministerium.gv.at;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu;
@ec.europa.eu
Subject: URGENT ‐ info about suspension
Dear
and Dear
,
We have been reading in the press reports about
.
Could we have more detailed info?
Members of the Steering Committee will be putting questions on this just ahead of finalisation of orders.
Best regards,
s
Sandra GALLINA
Deputy Director General
European Commission
DG SANTE
SANTE.DG1 in charge of Directions B and C
Office
B-1049 Brussels/Belgium
Tel. +32 2 29
Fax +32 2 29
xxxxxx.xxxxxxx@xx.xxxxxx.xx
AstraZeneca UK Limited is a company incorporated in England and Wales with registered number:03674842 and its registered
office at 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA.
This e-mail and its attachments are intended for the above named recipient only and may contain confidential and privileged
information. If they have come to you in error, you must not copy or show them to anyone; instead, please reply to this e-mail,
highlighting the error to the sender and then immediately delete the message. For information about how AstraZeneca UK Limited
and its affiliates may process information, personal data and monitor communications, please see our privacy notice at
www.astrazeneca.com